Company / FCF Margin
Matinas BioPharma Holdings, Inc. FCF Margin History
FY2015-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-628.9%
FY2023
5-year range
-46918.2% / -628.9%
FY2019-FY2023
Trend
+98.7%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from -46918.2% to -628.9% over the past 2 years.
Based on SEC 10-K filings.
-628.9% in FY2023 with a 5-year CAGR of +7656.3%.
Improved from -46918.2% to -628.9% over the past 2 years.
FCF Margin over time
Growth rates
- 3-Year Change
- +10343.9pp
- 5-Year Change
- +7656.3pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2023, fcf margin increased 98.7% year-over-year.
- Lowest fcf margin in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | -628.9% | +98.7% |
| FY2022 | -46918.2% | +0.0% |
| FY2021 | -46918.2% | -327.6% |
| FY2020 | -10972.8% | -21.0% |
| FY2019 | -9066.5% | -9.4% |
| FY2018 | -8285.1% | -104.2% |
| FY2017 | -4057.0% | - |
| FY2016 | - | - |
| FY2015 | -4057.0% | - |
As of FY2023 · SEC 10-K · Updated Jun 24, 2026